Tufail Muhammad, Cui Jia, Wu Changxin
Institute of Biomedical Sciences, Shanxi University Taiyuan 030006, Shanxi, China.
Department of Microbiology, Changzhi Medical College Changzhi 046000, Shanxi, China.
Am J Cancer Res. 2022 Jul 15;12(7):2920-2949. eCollection 2022.
Breast cancer (BC) affects over 250,000 women in the US each year. Drug-resistant cancer cells are responsible for most breast cancer fatalities. Scientists are developing novel chemotherapeutic drugs and targeted therapy combinations to overcome cancer cell resistance. Combining drugs can reduce the chances of a tumor developing resistance to treatment. Clinical research has shown that combination chemotherapy enhances or improves survival, depending on the patient's response to treatment. Combination therapy is a highly successful supplemental cancer treatment. This review sheds light on intrinsic resistance to BC drugs and the importance of combination therapy for BC treatment. In addition to recurrence and metastasis of BC, the article discussed biomarkers for BC.
乳腺癌（BC）每年在美国影响超过25万名女性。耐药癌细胞是大多数乳腺癌死亡的原因。科学家们正在开发新型化疗药物和靶向治疗组合，以克服癌细胞的耐药性。联合用药可以降低肿瘤产生治疗耐药性的几率。临床研究表明，联合化疗能否提高或改善生存率，取决于患者对治疗的反应。联合治疗是一种非常成功的辅助癌症治疗方法。这篇综述揭示了对乳腺癌药物的内在耐药性以及联合治疗对乳腺癌治疗的重要性。除了乳腺癌的复发和转移，本文还讨论了乳腺癌的生物标志物。
